Sacubitril Alone? A Statistician's Proposal
Executive Summary
FDA reviewer urged rejection of Novartis' Entresto because NDA did not meet combo reg, but offered alternative scenario: approve the novel component, sacubitril, alone for circumscribed indication in heart failure.